Comparative Pharmacology
Head-to-head clinical analysis: CORTIFOAM versus VALISONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORTIFOAM versus VALISONE.
CORTIFOAM vs VALISONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cortifoam (hydrocortisone acetate) is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to induce anti-inflammatory, antipruritic, and vasoconstrictive effects. It inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppresses immune cell migration and cytokine release.
Betamethasone valerate is a corticosteroid that induces phospholipase A2 inhibitory proteins (lipocortins), which control the release of arachidonic acid from membrane phospholipids, thereby inhibiting prostaglandin and leukotriene synthesis. It has anti-inflammatory, antipruritic, and vasoconstrictive effects.
1 applicatorful (90 mg hydrocortisone acetate) rectally twice daily for 2-3 weeks, then every other day as needed.
Topical: Apply a thin layer to affected skin once or twice daily. Maximum duration: 2 weeks.
None Documented
None Documented
Approximately 1.5-2 hours for hydrocortisone; clinically, effects persist longer due to local action.
Approximately 1.7 hours after topical application; systemic half-life is short due to rapid metabolism.
Primarily renal (about 70-90% as metabolites) and fecal (about 10-30% as metabolites).
Renal (primarily as metabolites, <5% unchanged); biliary/fecal elimination accounts for <10%.
Category C
Category C
Corticosteroid
Corticosteroid